Company Information
Industry 制造业
Company Introduction 浙江海正生物材料股份有限公司(以下简称“海正生材”或“公司”)是一家专注于聚乳酸的研发、生产及销售的高新技术企业,是一家掌握了纯聚乳酸制造和复合改性各关键环节核心技术,并实现多牌号聚乳酸的规模化生产和销售的公司。 公司秉承“开发植物资源,营造和谐社会”的价值观,以客户和市场为导向,打通了“乳酸-丙交酯-聚乳酸”的全工艺产业化流程、掌控了从材料合成到市场应用的各个环节,通过持续的研发创新,推动聚乳酸行业与下游材料应用行业的深度融合,为建设资源节约型、环境友好型社会贡献企业的力量。 在国内市场,公司取得了包括ISO9001质量管理体系认证、ISO14001环境管理体系认证和ISO45001职业健康安全管理体系认证在内的“三体系认证”;在国际市场上,公司已完成了欧盟REACH注册,得到了澳大利亚、德国、美国和奥地利的可堆肥认证,取得了美国FDA的食品接触安全认证。 自成立以来,公司不断提升聚乳酸产能并提高品质,产品质量获得国内外众多客户的认可。随着全球可降解塑料产业的进一步发展,聚乳酸制品应用日益广泛,海正生材未来将在聚乳酸制品的应用及推广的高科技产业化之路上不断前进。
Main Business 聚乳酸的研发、生产及销售
Legal Representative 郑柏超
Top Executives
董事长:郑柏超
董事:郑华苹,陈锡荣,郑柏超,乜君兴,陈志明,王海燕
独立董事:沈书豪,刘冉,王建祥
Top 5 Shareholder
Shareholder name Nature Holding Date
浙江海正集团有限公司限售股38.76%30/09/2024
中国石化集团资本有限公司流通A股7.74%30/09/2024
湖南中启洞鉴私募股权投资合伙企业(有限合伙)流通A股5.16%30/09/2024
中科应化(长春)科技有限公司流通A股4.54%30/09/2024
苏州市玮琪生物科技有限公司流通A股4.01%30/09/2024
Company Secretary 张敏
Solicitors 北京市康达律师事务所
Auditors 天健会计师事务所(特殊普通合伙)
Tel No 0576-88931556
Fax No 0576-88827723
Website www.hisunplas.com
Email hisunpla@hisunpharm.com
Company Address
Register: 浙江省台州市椒江区工人路293号301-07室
Office: 浙江省台州市台州湾新区台州湾大道188号
Listing Date 16/08/2022
Shares Capital
Shares Capital: 202,678,068
Total A Share: 202,678,068
Listed A Share: 117,727,907
Non-tradable A Share: 84,950,161
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.210
DPS(RMB)* ¥ 0.080
NBV Per Share(RMB)* ¥ 7.308
Market Capitalization(RMB) 1.223B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.